Work

Real-world (RW) characteristics and outcomes in platinum-resistant ovarian cancer (PROC) patients treated with mirvetuximab soravtansine (MIRV) monotherapy or single-agent chemotherapy (CTx).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.e17606

Authors: John K. Chan, Natalie L. Ayoub, Carmen Chen, Rajesh Kamalakar, Zahra Majd, Dana Meredith Chase

Institutions: Palo Alto Medical Foundation, California Pacific Medical Center, University of California, Irvine, AbbVie (United States), University of California, Los Angeles

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: AbbVie

OpenAlex ID: W7162691241

Cites:

Cited by:

Related to: